Quote | Precigen Inc. (NASDAQ:PGEN)
Last: | $1.47 |
---|---|
Change Percent: | 0.0% |
Open: | $1.51 |
Close: | $1.47 |
High: | $1.53 |
Low: | $1.46 |
Volume: | 382,097 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Precigen Inc. (NASDAQ:PGEN)
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Message Board Posts | Precigen Inc. (NASDAQ:PGEN)
Subject | By | Source | When |
---|---|---|---|
This target must be older than 1/2 USA population | NY1972 | investorshub | 04/23/2023 2:05:49 AM |
Of all the targets they chose mesothelin! https://www.prnewswire.com/news-releas | jondoeuk | investorshub | 04/22/2023 1:19:06 AM |
It makes little sense for them to waste | jondoeuk | investorshub | 04/04/2023 8:39:09 PM |
$LYEL has an anti-ROR1 CAR-T in the clinic, | jondoeuk | investorshub | 04/03/2023 7:02:36 PM |
Wow, just over 17 months since they filed | jondoeuk | investorshub | 04/03/2023 6:57:36 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...